Facebook Pixel

Vaccine for Type 1 Diabetes

Rate This

The Diamyd vaccine is currently being tested as a means to slow or stop the progression of type 1 diabetes in recently diagnosed patients, age 10 to 20 years. Reference 1 describes two phase-3 trials in progress, one in the United States and one in Europe. Results from phase-2 trials are encouraging.

Type 1 diabetes is generally considered to be an autoimmune disorder which destroys the insulin-secreting beta cells of the pancreas. In rare cases, patients go into complete remission shortly after diagnosis. Partial remission is more common, and many patients are able to produce some insulin for considerable time periods after diagnosis. This residual insulin secretion is of great importance, since it reduces blood glucose fluctuations and the risk of complications.

Over the last three decades, research into immune modulation therapy for type 1 diabetes has shown promising results. Cyclosporin, the immunosuppressive drug best known for organ transplant therapy, demonstrated significant preservation of insulin secretion. Unfortunately, the side effects were considered worse than the original condition of type 1 diabetes. Other immune intervention therapies have been tried, including azathioprine, linomide, antithymocyte globulin, prednisone, antioxidants, immunoglobulins, photopheresis, and plasmapheresis. The risks were judged to be greater than the benefits, but the studies led to further ideas for therapy.

Early studies on plasmapheresis uncovered a variant form of glutamic acid decarboxylase (GAD) in the blood of children with diabetes. Autoantibodies to GAD have been identified as antigens for autoimmune diabetes. The Diamyd vaccine was developed to modulate the immune response to GAD, with the goal of preserving beta cell function and insulin secretion.

For children at risk for type 1 diabetes, the vaccine is being tested in Europe as a preventive measure. Similar trials are under discussion for the United States.

Type 1 diabetes was once called juvenile onset diabetes, but it is now recognized that adults of any age can develop this condition.

Add a Comment2 Comments

EmpowHER Guest

Hi Linda! Did you know the DiaPrevent diabetes research study is available in the US? The study is enrolling 10 to 20 year olds recently diagnosed with Type 1 Diabetes.

In this phase III study, two out of three participants receive active drug and one out of three participants receives placebo (shots that look the same but without the active drug). Diamyd's active substance is a protein called glutamic acid decarboxylase (GAD).

The study is open only to US residents. Participation is strictly voluntary. Find out more at http://www.diaprevent.com

July 13, 2010 - 5:19am
EmpowHER Guest

This is a rare diabetes article; one that focuses on Type 1 instead of "fat American" Type 2 diabetes. If only it were the other way around.

July 6, 2010 - 3:06pm
Enter the characters shown in the image.
By submitting this form, you agree to EmpowHER's terms of service and privacy policy
Add a Comment

We value and respect our HERWriters' experiences, but everyone is different. Many of our writers are speaking from personal experience, and what's worked for them may not work for you. Their articles are not a substitute for medical advice, although we hope you can gain knowledge from their insight.


Get Email Updates

Diabetes Guide

Have a question? We're here to help. Ask the Community.


Health Newsletter

Receive the latest and greatest in women's health and wellness from EmpowHER - for free!